Pharming Group (PHGUF) has released an update.
Pharming Group has initiated a Phase II clinical trial for leniolisib, targeting primary immunodeficiencies with immune dysregulation, at the National Institutes of Health. The trial will assess safety, tolerability, and efficacy in approximately 12 patients with conditions like ALPS-FAS and CTLA4 haploinsufficiency, aiming to inform future Phase III programs. Leniolisib, already approved for APDS in several countries, is being explored for its potential to address similar immune dysregulations in a range of rare PID disorders.
For further insights into PHGUF stock, check out TipRanks’ Stock Analysis page.
